Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
September 26 2022 - 8:00AM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on the discovery and development of targeted cell
therapies for patients with autoimmune diseases, today announced
that Steven Nichtberger, M.D., President and Chief Executive
Officer, will participate in a fireside chat at the Chardan 6th
Annual Genetic Medicines Conference on Monday, October 3, 2022 at
4:00 p.m. ET in New York, NY.
A live webcast of the presentation will be
available on the News and Events section of the Company’s website
at www.cabalettabio.com. Replays of the presentation will be
available on the website for 30 days.
About Cabaletta BioCabaletta Bio (Nasdaq: CABA)
is a clinical-stage biotechnology company focused on the discovery
and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™
platform, in combination with Cabaletta Bio’s proprietary
technology, has advanced a growing pipeline that currently includes
potential treatments for patients with mucosal pemphigus vulgaris,
MuSK-associated myasthenia gravis, PLA2R-associated membranous
nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with
FVIII alloantibodies. Cabaletta Bio’s headquarters are located in
Philadelphia, PA. For more information,
visit www.cabalettabio.com and follow us on LinkedIn.
Contacts:
Anup MardaChief Financial Officerinvestors@cabalettabio.com
Sarah McCabeStern Investor Relations,
Inc.sarah.mccabe@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Sep 2023 to Sep 2024